RxDoctor Payments Data

Jennifer Albrecht, DO

Family Medicine · Lima, NYNPI 1497018139

Payments from drug & device makers

$955in general payments, 2019–2025

Across 58 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$255
  • Novo Nordisk$104
  • Novartis$90
  • Genentech USA, Inc.$66
  • Astellas Pharma US Inc$50
  • Amgen$42
  • plus $347 from 18 others

What the payments were for

  • Food & beverage$81585%
  • Education$14015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$10,169
Medicare patients
36
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$14,148
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,962
Incruse ElliptaUmeclidinium Bromide11$3,757
Rosuvastatin Calcium100$1,783
Levothyroxine Sodium126$1,348
Atorvastatin Calcium68$1,084
Potassium Chloride21$1,081
SynthroidLevothyroxine Sodium14$1,052
Duloxetine Hcl43$957
Chlorthalidone24$879
Gabapentin34$866
Albuterol Sulfate HfaAlbuterol Sulfate34$837
Losartan Potassium64$775
Lisinopril69$708
Omeprazole35$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$14,14816 claims
GSKTrelegy Ellipta, Incruse Ellipta$16$10,71922 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,348126 claims
AbbVieSynthroid$11$1,05214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Lima

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →